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 It is of great clinical importance to use the 
best available means to monitor the pro-
gression of chronic kidney disease (CKD) 
so that appropriate necessary preventive 
measures can be instituted. In the manage-
ment of CKD, secondary prevention is 
related to many common risk factors that 
are present in a large proportion of the 
population; these include diabetes, high 
blood pressure, cardiovascular disease, and 
other factors related to the individual ’ s life-
style. Secondary prevention, however, 
requires a timely diagnosis of CKD and an 
accurate periodic assessment of the progres-
sion of renal damage. In most renal diseases, 
long-term clinical outcome is determined 
by the severity of accompanying tubulo-
interstitial disease. Therefore, sensitive 
markers of tubular injury, which can be 
used to identify or confi rm the presence of 
epithelial-cell injury even when morpho-
logical changes are minimal, would be help-
ful in the evaluation of renal patients. 
 Diabetic nephropathy is a serious com-
plication with high morbidity and mortal-
ity. Despite improved outcome due to 
aggressive multipronged management, 
many patients still develop end-stage renal 
disease. Recently, studies have shown that 
not only glomerular but also tubulointer-
stitial damage is an important factor in the 
progression of diabetic nephropathy 
 ( Figure 1 ). 1 Clinically, diabetic nephro pathy 
is characterized by the onset of hyperfi ltra-
tion and microalbuminuria that are fol-
lowed by sustained proteinuria with 
ensuing declining renal function. The 
microalbuminuria and proteinuria, in gen-
eral, are refl ective of glomerular damage. 
Interestingly, the pathophysiology of pro-
teinuria and tubulointerstitial damage has 
been found to be intertwined. By reabsorp-
tion of increased amounts of  protein from 
the tubular lumen, pro infl ammatory and 
profi brotic responses are induced in tubular 
cells. 2 Th is leads to infl ammation and fi bro-
sis in the tubulointerstitial compartment. 
In addition, it is known that proteinuria 
causes tubular-cell apoptosis. Th e severity 
of tubulointerstitial damage predicts a 
blunted response to renoprotective inter-
vention, with a worse long-term clinical 
outcome, which can be ameliorated by 
aggressive treatment. Thus, to identify 
patients who need such management, it is 
imperative to select appropriate sensitive 
biomarkers that would be specifi cally suit-
able for the assessment of the degree of 
tubulointerstitial damage. Markers of tubu-
lar damage could therefore potentially be 
useful in the evaluation of prognosis and 
for monitoring the eff ectiveness of treat-
ment in diabetic nephro pathy. Several dif-
ferent markers of tubular damage have been 
suggested in recent years. 
 Nielsen  et al. 3 (this issue) investigated the 
reliability of urinary excretion of neutrophil 
gelatinase-associated lipocalin (NGAL), 
kidney injury molecule-1 (KIM-1), and 
liver – fatty acid-binding protein (LFABP) 
as markers of progression of diabetic 
nephropathy. 
 Neutrophil gelatinase-associated lipoca-
lin (NGAL) is a small, 25-kDa protein 
released from tubular cells after acute 
 kidney injury (AKI). It seems to be one of 
the important biomarkers in the detection 
of AKI. Its levels, in both urine and plasma, 
rise with the onset of AKI, preceding the 
increase of serum creatinine. However, 
recent studies also suggest NGAL as a pos-
sible marker of CKD. In fact, mean urinary 
NGAL concentrations have been found to 
be higher in CKD patients. 4 Furthermore, 
urinary NGAL concentrations were sig-
nifi cantly correlated with serum creatinine 
levels and the degree of proteinuria. NGAL 
is an emerging and promising marker for 
the staging of CKD. However, many limita-
tions were reported, and its use in routine 
assessment of renal function in patients 
with CKD cannot be recommended. 5 
 Kidney injury molecule-1 (KIM-1) is 
expressed in proximal tubules, and it is 
regarded as a hallmark biomarker of a pro-
teinuric state, and toxic and ischemic renal 
injury. Recently, much attention has been 
paid to its possible pathophysiological role 
in modulating tubular damage and repair. 
Conceivably, KIM-1 facilitates repair of 
the damage by removing cellular debris 
and apoptotic bodies from the injured 
tubulointerstitial compartment. Th is raises 
an exciting prospect for the development 
of novel therapeutic strategies targeted at 
KIM-1. However, it remains to be seen 
whether or not stimulation of KIM-1 is 
beneficial in boosting the reparative 
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 processes to restore tubular functions. 
Some investigators believe that KIM-1 
may be a predictive marker of CKD in 
addition to AKI. 6 In this regard, rats with 
protein overload nephropathy have 
increased urinary KIM-1 excretion, as do 
patients with proteinuria in the CKD state, 
who may be at risk of progression to renal 
failure. Th e level of urinary excretion of 
KIM-1 at the time of initiation of therapy 
may be predictive of the degree of antici-
pated renal damage with ensuing recovery. 
Rats with higher pretreatment KIM-1 lev-
els have worse outcomes. So far, long-term 
follow-up data on the prognostic signifi -
cance of urinary KIM-1 in human renal 
disease are somewhat sparse. Positive 
KIM-1 staining in proximal tubules cor-
relates well with the degree of injury and 
deterioration of allograft  functions. At the 
same time, high urinary KIM-1 excretion 
was found to correlate with graft  loss in 
renal transplant recipients; this was inde-
pendent of creatinine clearance, donor 
age, and, in particular, the proteinuria. 
Th is biomarker therefore may serve as a 
promising candidate for noninvasive mon-
itoring of the critical pathophysiological 
processes. Indeed,  urinary KIM-1 is 
reduced by antiproteinuric therapy, irre-
spectively of the treatment regimen or 
reduction in blood pressure. It is likely that 
the decrease in urinary KIM-1 by antipro-
teinuric therapy may have also reduced the 
tubulointerstitial damage. Nielsen  et al. 3 
also report that the angiotensin II receptor 
blocker losartan significantly (43 % ) 
reduced the urinary excretion of KIM-1. 
Experimental studies in diabetic rats have 
also shown that renin – angiotensin system 
blockade reduces apoptotic factors and 
thereby preserves tubular functions. 7 Kelly 
 et al. hypothesized that the reduction in 
tubular damage seen in these animals with 
blockade of the renin – angiotensin system 
is due to a decrease in the oxidative stress 
and correction of chronic hypoxia and is 
independent of the blood pressure-lower-
ing eff ect. Th e studies described above, 
however, do not conclusively establish that 
KIM-1 has prognostic value selectively 
with regard to proteinuria, independent of 
other variables. Future long-term studies 
should investigate the independent prog-
nostic impact of KIM-1 and proteinuria in 
order to develop individual specifi c treat-
ment targets. If so, it might be worthwhile 
to test whether targeting KIM-1, in addi-
tion to antiproteinuric therapy, can 
improve the outcome of progressive loss of 
renal function. Th e limitations referred to 
above of NGAL as a marker of CKD pro-
gression also apply to KIM-1. 5 
 Liver – fatty acid-binding protein 
(LFABP) is an intracellular carrier protein 
that is expressed in the proximal tubules 
in the kidney and liver and is believed to 
be endowed with protective functions. By 
immunohistochemical staining of renal 
biopsy specimens, it has been shown that 
urinary LFABP (u-LFABP) excretion is 
associated with structural and functional 
tubular damage. Th is was confi rmed in a 
number of diseases with proteinuria lead-
ing to tubular damage and CKD, including 
minimal-change nephrotic syndrome, 
lupus nephritis, and diabetic nephropathy. 
A study in CKD showed that serum 
LFABP levels do not aff ect the u-LFABP 
level, which suggests that there is no trans-
glomerular passage of LFABP in CKD, and 
that the LFABP measured in urine origi-
nates primarily from tubular cells. 8 Th e 
u-LFABP excretion increases with the 
deterioration of renal function, with no 
relation to urinary protein excretion. How-
ever, u-LFABP was found to be increased 
in patients with hypertension or diabetes 
even in the absence of kidney damage. 
Th erefore, data regarding u-LFABP as a 
reliable clinical biomarker for monitoring 
CKD await further evaluation. 5 
 Th e studies carried out over the past few 
decades indicate that in spite of a reduc-
tion in proteinuria, progression of renal 
tubulointerstitial damage can still ensue. 
So, individualized therapies to reduce pro-
teinuria and tubulointerstitial damage can 
be instituted only when distinct biomark-
ers refl ective of tubulointerstitial injury 
can be developed. It is fairly established 
that reduced renal function correlates bet-
ter with the injury to the tubulointerstitial 
compartment than with glomerular dam-
age. 9 However, the selective contribution 
of the tubulointerstitial compartment that 
would be refl ected in the deterioration of 
renal function has not been clearly estab-
lished. Th e results of Nielsen  et al. 3 seem 
to exclude an independent contribution 
of the tubulointerstitium in the progres-
sive deterioration of renal function in dia-
betic nephropathy. In fact, a lack of 
correlation between three biomarkers of 
tubular damage and glomerular fi ltration 
rate was found when the proteinuria was 
taken into account in statistical analyses. 
Th is may be due to the fact that damage in 
the glomerular and tubulointerstitial com-
partments is intricately interwoven, since 
proteinuria by itself induces tubular 
injury. As a consequence, it is diffi  cult to 
envision involvement of the tubulointer-
stitium that would be independent of 
 proteinuria in diabetic nephropathy, 
whose progression to end-stage renal 
 disease is strictly connected to the degree 
of proteinuria. So it is not surprising that 
Nielsen  et al. 3 did not fi nd an independent 
correlation between the markers of  tubular 
damage and decline of renal function in 
diabetic nephropathy. Conceivably, these 
 Figure 1  |  Photomicrograph depicting concomitant involvement of glomerular and 
tubulointerstitial compartments in diabetic nephropathy. Asterisks represent the 
Kimmelstiel-Wilson nodular lesions in the affected glomerulus. The arteriole (ART) has undergone 
hyalinosis. The interstitium (INT) is expanded, and tubular basement membranes (TBM) are thickened. 
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markers are better reflective of acute 
injury of tubular cells than of chronic 
interstitial damage. Thus, in chronic 
slowly progressive diseases, one should 
not expect a signifi cant increase in urinary 
excretion of markers refl ective of severe 
acute tubular-cell damage. At present, no 
solid data are available in support of a role 
for tubulointerstitial biomarkers in 
routine clinical use for the follow-up of 
CKD. Tests that can measure  per se the 
actual tubular function instead of acute 
tubular-cell damage may eventually be 
useful in assessment of chronic tubulo-
interstitial disease. 
 The question arises of how one can 
measure renal function to assess the effi  -
cacy of treatment intended to dampen the 
progression of renal damage. Creatinine 
and its derivative formulae, and creatinine 
clearance, are not the best markers to 
gauge renal function in the presence of 
proteinuria. 10 Th e use of low-molecular 
weight proteins, such as cystatin C, also 
does not add much value to assessment of 
renal function. Even when cystatin C and 
plasma creatinine together were taken into 
the equation, they were found to be insen-
sitive in detecting low-level reduction in 
the nephron mass, parti cularly in patients 
with well-preserved renal  function. 11 – 13 
 Finally, the experience of decades indi-
cates that the direct measure of glomerular 
fi ltration rate seems ideally suited to assess 
renal function. However, the routine use 
of exogenous substances poses a dilemma. 
Simplified radioisotopic methods have 
been proposed, which may be of real prac-
tical use in nephrology centers where a 
large number of patients can be seen. Th us, 
it seems that routine estimation of renal 
function can be gauged by measurement 
of plasma creatinine or cystatin C and their 
derivative formulae, but periodic checking 
of the true glomerular filtration rate is 
advisable, and the use of tubular markers 
to assess the  progression of diabetic neph-
ropathy and thus to infl uence therapeutic 
regimens seems premature at present. 
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 Vascular calcifi cation is highly prevalent 
in patients with kidney disease and is 
associated with increased risk of cardio-
vascular events and death. 1 Once thought 
to be a passive degenerative process, vas-
cular calcifi cation is now known to be a 
highly orchestrated process characterized 
by significant phenotypic changes and 
molecular reprogramming that entrains a 
repertoire of transcription factors and 
osteogenic programs. 
 Th ere are multiple mechanisms for vas-
cular calcifi cation. Particularly relevant to 
vascular calcifi cation in patients with kid-
ney disease are the mechanisms related to 
increased phosphate. 2 Elevated serum 
 Phosphate, oxidative stress, and 
nuclear factor-  B activation 
in vascular calcification 
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 Phosphate-induced vascular calcification, characterized by 
induction of osteogenic programs, mineral vesicle release, and 
apoptosis, is prevalent in patients with kidney disease. Zhao  et al. 
provide a mechanistic link between phosphate-induced calcification 
and increased mitochondrial membrane potential, increased 
mitochondrial reactive oxygen species, activation of the nuclear 
factor-  B pathway, and subsequent expression of osteogenic genes 
and vascular mineralization. This link clarifies the intracellular 
mechanism of vascular calcification and may allow exploration of 
antioxidants as therapeutic agents for vascular calcification. 
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